Saturday 17 October 2026 Export URGN’s income statement to Excel — free account

Urogen Pharma

Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024. In the quarter to June 2026, revenue grew 199.2%, EPS grew 73.3%, free cash flow grew 17.3% and total debt rose 56.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

34.56 2.05 −5.60%

Follow URGN

Alert me

Market cap: $1.8B
P/E: 0.0×
Fwd P/E: −30.0×
Dividend yield: —
F-score: 2/9
Altman Z: −5.16
Beneish M: −1.42
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 4.77

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	2	—	—	1	2	1	1	2	1

Insider Ownership 17.63%

Capital & Financial Ratios $m

Market Cap 1,790.00

Revenue 188.73

Net Income (97.64)

Free Cash Flow (159.13)

Net Debt 82.37

Current Ratio 3.80

Debt/Equity (1.45)

P/E ratio 0.00

Fwd P/E (30.00)

P/S ratio 9.23

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 92.99%

Next Y EPS Growth 1,223.70%

Next Y revenue growth 193.47%

Next 5Y EPS Growth 50.33%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 47.46%

10-year low 10-year high

EV/Sales against its own 10 years 53.98%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	138	238	122	109
Receivables	15	20	33	89
Inventory	6	9	16	25
Other	—	—	—	—
	169	276	186	235

	2023	2024	2025	Q'26
Payables	17	27	28	40
ST’ Debt	—	—	—	—
Other	4	8	5	8
	31	46	46	62

Compound Annual Growth %

	10y	5y	3y
Sales	—	56.22%	19.49%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	51	72	—	—	—
’25	20	24	27	38	110
’24	19	22	25	25	90
’23	17	21	21	24	83
’22	14	17	16	18	64
’21	7	13	11	16	48
’20	—	0	3	8	12

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(45)	(33)	—	—	—
’25	(42)	(40)	(42)	(38)	(162)
’24	(32)	(24)	(28)	(14)	(97)
’23	(26)	(20)	(17)	(13)	(76)
’22	(24)	(24)	(18)	(22)	(88)
’21	(27)	(19)	(18)	(20)	(85)
’20	(36)	(24)	(25)	(21)	(106)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(45)	(33)	—	—	—
’25	(42)	(40)	(42)	(38)	(163)
’24	(32)	(24)	(28)	(14)	(97)
’23	(26)	(20)	(17)	(13)	(77)
’22	(24)	(24)	(18)	(22)	(88)
’21	(28)	(19)	(19)	(20)	(86)
’20	(36)	(24)	(26)	(21)	(107)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.47)	(0.28)	—	—	—
’25	(0.92)	(1.05)	(0.69)	(0.54)	(3.19)
’24	(0.97)	(0.91)	(0.55)	(0.80)	(2.96)
’23	(1.30)	(1.03)	(0.68)	(0.72)	(3.55)
’22	(1.25)	(1.18)	(1.13)	(1.22)	(4.79)
’21	(1.17)	(1.17)	(1.35)	(1.27)	(4.96)
’20	(1.79)	(1.44)	(1.31)	(1.38)	(5.90)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	13.01	36.95	20.72	13.12	8.68	4.85	7.60	10.26	3.42	Analyst estimates 2026–2028 Powerpack
	High	—	44.63	69.57	55.49	35.00	28.20	12.63	24.13	20.70	30.00
People
People	Employees	33	46	78	173	187	195	200	201	235	291
	Revenue/emp, $m	0.53	0.18	0.01	0.00	0.06	0.25	0.32	0.41	0.38	0.38
Income, $m
Income, $m	Revenue	18	8	1	0	12	48	64	83	90	110
	Gross margin, %	99.84	92.65	(59.84)	100.00	91.45	89.27	88.11	88.68	90.18	88.66
	EBT	(2)	(20)	(76)	(105)	(125)	(109)	(108)	(98)	(124)	(153)
	EBT margin, %	(11.07)	(244.93)	(6,696.10)	(584,144.44)	(1,060.34)	(227.66)	(167.86)	(118.87)	(137.22)	(139.74)
	Net income	(2)	(20)	(76)	(105)	(128)	(111)	(110)	(102)	(127)	(153)
	Depreciation	0	0	0	0	1	1	0	0	(3)	(2)
Per share, $
Per share, $	Revenue	7.60	0.84	0.07	0.00	0.54	2.15	2.82	2.87	2.11	2.28
	Earnings	(0.84)	(2.14)	(4.80)	(5.12)	(5.90)	(4.96)	(4.79)	(3.55)	(2.96)	(3.19)
	Cash flow	1.82	(0.98)	(2.37)	(3.46)	(4.86)	(3.80)	(3.84)	(2.65)	(2.26)	(3.38)
	Capex	(0.30)	(0.03)	(0.04)	(0.02)	(0.06)	(0.03)	(0.01)	(0.01)	(0.01)	(0.01)
	Free cash flow	1.52	(1.01)	(2.41)	(3.48)	(4.92)	(3.83)	(3.85)	(2.66)	(2.26)	(3.38)
	Book value	7.07	7.05	5.72	8.78	4.42	0.38	(3.92)	(2.26)	(0.21)	(2.19)
	Shares, m	2	10	16	21	22	22	23	29	43	48
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	601.39	1,030.15	33.21	4.42	3.06	5.30	5.05	10.26
	P/B	1.98	5.48	7.53	3.80	4.07	25.26	0.00	0.00	0.00	0.00
	EV/Sales	0.00	0.00	511.34	812.12	24.60	2.55	3.01	4.83	3.77	10.30
	EV/FCF	21.38	(30.72)	(15.22)	(7.57)	(2.71)	(1.43)	(2.21)	(5.22)	(3.51)	(6.95)
Cash, $m
Cash, $m	Operating cash flow	4	(10)	(37)	(71)	(106)	(85)	(88)	(76)	(97)	(162)
	Capex	(1)	0	(1)	0	(1)	(1)	0	0	0	0
	Free cash flow	3	(10)	(38)	(71)	(107)	(86)	(88)	(77)	(97)	(163)
Balance, $m
Balance, $m	Working capital	19	67	89	129	94	92	105	138	230	140
	Total debt	—	—	—	3	1	0	98	99	122	122
	Net debt	(21)	(73)	(102)	(145)	(102)	(90)	(3)	(39)	(116)	0
	Shareholders’ equity	16	69	90	180	96	8	(89)	(65)	(9)	(105)
Returns, %
Returns, %	ROA	(9.15)	(40.57)	(84.48)	(68.73)	(79.22)	(91.68)	(85.98)	(65.14)	(54.68)	(63.14)
	ROIC	0.00	0.00	0.00	(193.80)	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(11.92)	(47.16)	(95.40)	(77.77)	(92.88)	(211.55)	271.24	132.29	342.83	268.63

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MRVI Maravai LifeSciences Holdings, Inc.	$1.8B	— (loss-making)	— (loss-making)	+8.53% (above 0%: growing)	n/m	+127.57% (above 0%: growing)	40.14%	(29.33%)	Compare
ZYME Zymeworks Inc.	$1.8B	— (loss-making)	16.2×	−90.58% (below 0%: shrinking)	n/m	−385.53% (below 0%: shrinking)	(497.71%)	(918.95%)	Compare
PVLA Palvella Therapeutics, Inc.	$1.8B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%	Compare
MESO Mesoblast Limited	$1.8B	— (loss-making)	—	−13.41% (below 0%: shrinking)	n/m	−89.23% (below 0%: shrinking)	(353.35%)	(909.40%)	Compare
URGN Urogen Pharma	$1.8B	— (loss-making)	— (loss-making)	+199.22% (above 0%: growing)	n/m	+17.26% (above 0%: growing)	90.93%	0.15%
XNCR Xencor, Inc.	$1.8B	— (loss-making)	— (loss-making)	+17.46% (above 0%: growing)	n/m	−52.91% (below 0%: shrinking)	100.00%	(72.37%)	Compare
VIR Vir Biotechnology, Inc.	$1.8B	— (loss-making)	— (loss-making)	+19,582.54% (above 0%: growing)	n/m	+200.47% (above 0%: growing)	100.00%	30.75%	Compare
SEPN Septerna, Inc.	$1.8B	— (loss-making)	— (loss-making)	+22,375.63% (above 0%: growing)	n/m	−9.01% (below 0%: shrinking)	100.00%	(62.95%)	Compare
BHVN Biohaven Ltd.	$1.7B	— (loss-making)	— (loss-making)	+131.43% (above 0%: growing)	n/m	+49.13% (above 0%: growing)	0.00%	0.00%	Compare
Median of peers	$1.8B	—	—	+13.00%	—	−30.96%	70.07%	(46.14%)

All 614 Biotechnology stocks →

Urogen Pharma (URGN) key facts

Strength: Urogen Pharma’s revenue for fiscal 2025 (year ended December 2025) was $109.8 million, up 21.4% from fiscal 2024.
Urogen Pharma (URGN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, URGN traded at $34.56, a market capitalization of $1.8 billion.
Return on equity was 268.6% and debt-to-equity -1.45.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −5.16 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.